Thus, we hypothesize that celecoxib may effectively delay the progression of hepatic steatosis to advanced liver diseases in individuals with hepatic metabolic alterations induced by the insulin‐driven activation of PI3K/AKT/mTORC1 signalling in hepatocytes. Here, INS is linked to liver disorder.